Liquidia Provides Update on Clinical Pipeline Targeting PAH

Enrolled first PH-ILD patient in the open-label ASCENT study of YUTREPIAConfirmed with FDA that a single pivotal efficacy trial with L606 will support PAH and PH-ILD indications MORRISVILLE, N.C.,...

Related Keywords

United States , Delaware , America , Jason Adair , Pharmosa Biopharm , United Therapeutics Corporation , Liquidia Corporation , Drug Administration , Us District Court , Liquidia Technologies Inc , York Heart Association , Open Label Prospective Multicenter Study , Evaluate Safety , Dry Powder Inhaled Treprostinil , Pulmonary Hypertension , Prescription Drug User Fee Act , Chief Medical Officer , New York Heart Association , Functional Class , New Drug Application , Dry Powder Inhalation , Liquidia Technologies , United Therapeutics , Private Securities Litigation Reform Act , Markets ,